Home » Genmab Reports on Recruitment in HuMax-CD20 Study
Genmab Reports on Recruitment in HuMax-CD20 Study
Denmark’s Genmab has recruited 132 patients in a study of HuMax-CD20 for the treatment of refractory chronic lymphocytic leukemia.
The group includes 66 patients who are refractory to fludarabine and alemtuzumab and 66 fludarabine-refractory patients who are considered inappropriate candidates for alemtuzumab due to a bulky tumor in their lymph nodes.
An interim analysis will be conducted when 24-week efficacy data are available. The study will remain open for recruitment to collect additional safety and efficacy data, Genmab said.
HuMax-CD20 (ofatumumab) is a monoclonal antibody being developed under an agreement between Genmab and GlaxoSmithKline.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May